Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
about
MEK and PI3K inhibition in solid tumors: rationale and evidence to datePI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasmsCIViC databasePhase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyA framework for genomic biomarker actionability and its use in clinical decision makingChemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinomaType III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.The biology and clinical development of MEK inhibitors for cancer.Developing biomarker-specific end points in lung cancer clinical trials.MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.Ocular toxicities of MEK inhibitors and other targeted therapies.Allosteric modulators of MEK1: drug design and discovery.A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib.A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.Copaifera of the Neotropics: A Review of the Phytochemistry and Pharmacology.
P2860
Q26775573-46DF2362-2056-4F2E-AC94-B1958A1C5C4EQ26862544-10625124-D236-4A96-A3D7-8D394F8FD545Q27612411-CED78BDA-4DA1-4EEC-8F30-759441ED6E4BQ30313606-B9FD1341-FCF1-4797-871C-111CBAED1602Q33830941-E060C125-D648-469D-8E03-3749331A9FBCQ34781122-5C5F1479-4313-407B-8F39-FC803D90C638Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713Q37285551-749F5407-C2ED-4405-A1FE-A3CA114E1DECQ37339708-AE2AA13D-8341-413C-8BAC-C13A5A497CDBQ37640001-18A732ED-CEA9-4FA1-B7AC-1AD7D0E2FB59Q38199737-BD40AB8A-FA2A-4623-819C-AC638AAC52E1Q38270129-7185AD69-8C04-4C3D-8F28-AE1DEB2E6F5DQ38297892-3C13DA72-7CD3-4AB4-B0DF-C2CD9A5CBE6EQ38444096-B5731068-0FBB-429A-804D-3CDDB234FCD4Q38764273-D49E2DBE-C414-43BA-BBFE-DE73DA58D2CDQ38817910-74441636-99AC-40DD-85A0-F9576ED2E515Q46780069-D70B6237-322F-4AFD-B0AD-F3FEC2CC98C3Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572Q53569776-D380C668-1F6C-41B5-A883-FDC8F51F8B9EQ55083491-348A4EC8-2011-4F9D-99F0-D4C9C7716E9D
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մարտին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Multicenter phase I trial of t ...... patients with advanced cancer.
@ast
Multicenter phase I trial of t ...... patients with advanced cancer.
@en
Multicenter phase I trial of t ...... patients with advanced cancer.
@nl
type
label
Multicenter phase I trial of t ...... patients with advanced cancer.
@ast
Multicenter phase I trial of t ...... patients with advanced cancer.
@en
Multicenter phase I trial of t ...... patients with advanced cancer.
@nl
prefLabel
Multicenter phase I trial of t ...... patients with advanced cancer.
@ast
Multicenter phase I trial of t ...... patients with advanced cancer.
@en
Multicenter phase I trial of t ...... patients with advanced cancer.
@nl
P2093
P3181
P1476
Multicenter phase I trial of t ...... patients with advanced cancer.
@en
P2093
Alex A Adjei
Beth Sheedy
Colin D Weekes
Cory Iverson
Daniel D Von Hoff
Diane P Leffingwell
Glen J Weiss
Grace K Dy
Jeffrey N Miner
Karl D Lewis
P304
P3181
P356
10.1158/1078-0432.CCR-12-3529
P407
P577
2013-03-01T00:00:00Z